+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07223814

Bleximenib Combined With Standard Chemotherapy and Maintenance Therapy for Adults With Newly Diagnosed AML Featuring KMT2A or NPM1 Mutations

Led by Stichting Hemato-Oncologie voor Volwassenen Nederland · Updated on 2026-10-08

875

Participants Needed

98

Research Sites

182 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the addition of bleximenib, a drug that blocks a specific protein interaction in leukemia cells, to standard chemotherapy for adults with newly diagnosed acute myeloid leukemia AML who have mutations in the NPM1 or KMT2A genes. This phase 3, randomized, double-blind, placebo-controlled trial aims to see if bleximenib improves treatment outcomes compared to chemotherapy alone. Participants will be randomly assigned to one of three groups standard chemotherapy plus bleximenib with bleximenib maintenance, standard chemotherapy plus bleximenib with placebo maintenance, or standard chemotherapy plus placebo with placebo maintenance. Treatment continues until disease progression, unacceptable side effects, or other criteria require stopping. After the treatment phase, all participants will be followed observationally for up to four years to compare long-term outcomes. During the study, participants will receive standard chemotherapy drugs including cytarabine and daunorubicin or idarubicin, alongside the study drug or placebo. Researchers will monitor event-free survival as the primary outcome over up to four years and five months. Secondary outcomes include overall survival, remission rates, duration of remission, and the percentage undergoing stem cell transplantation, with follow-up extending up to nearly eight years. Safety and treatment effects will be closely observed throughout the study period.

CONDITIONS

Brief Title

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Research Team

M

M.H.G.P. Raaijmakers

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here